Search

Acute management of retrobulbar haemorrhage

The authors discuss the importance of rapid diagnosis and correct management of acute RBH presentation to avoid the risk of permanent blindness. Retrobulbar haemorrhage (RBH) is an ocular emergency that occurs due to arterial bleeding in the orbital cavity behind...

Insects, swelling and sight loss: a case of orbital inflammatory syndrome

Despite being the most common cause of painful orbital mass in adults and the third most common orbital disease, orbital inflammatory syndrome still proves to be a difficult ocular condition to diagnose, treat, and manage. A 41-year-old lady presented to...

My top five: Emerging alternatives to manage and treat nAMD

Wet (exudative or neovascular) age-related macular degeneration (AMD) is characterised by choroidal neovascularisation, in which new blood vessels from the choroid invade through Bruch’s membrane. These blood vessels proliferate beneath or through the retinal pigment epithelium (RPE), causing patients to...

Managing an outreach eye service… 8000 miles away!

In 1997, Paul Rosen, a relatively newly appointed consultant surgeon to the Oxford Eye Hospital, was approached by Richard Davies, a GP in Stanley, Falkland Islands, to assist in the provision and management of the Falkland Islands eye surgery service....

You want to do paediatric ophthalmology? Seriously?

Completion of Core Training is approaching fast and you begin to wonder three things. One, where do you want to live? Two, is anyone going to be retiring there soon? Three, what subspecialty do you want to do? In an...

Quality matters in the management of serious eye disorders

The author discusses the first quality standard for serious eye disorders from NICE and takes a look at new care models for enhanced service delivery. Patient backlogs pose risks to patient safety, with research showing that people are losing sight...

Broadening of treatment options for potentially blinding retinal conditions

Rod McNeil provides an update on a promising bispecific antibody recently approved for treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) and considers emerging developments in biosimilars to established anti-vascular endothelial growth factor (anti-VEGF) therapies, including...